Pharmachologic effect Recombinant human erythropoietin (purified glycoprotein), which is a hematopoietic growth factor. Obtained by the method of genetic engineering. Increases the number of erythrocytes, reticulocytes, stimulates the synthesis of hemoglobin in cells. Has no effect on leukopoiesis. It is believed that erythropoietin interacts with specific erythropoietin receptors on the cell surface.
Pharmacokinetics After SC administration, Cmax in plasma is achieved after 12-28 hours T1 / 2 in the final phase - 13-28 hours.
After intravenous administration of T1 / 2 active substance is 4-12 hours.
Indications Pronounced anemia, which occurs against a background of chronic renal failure.
Anemia in the lesions of the bone marrow and some chronic diseases (including aplastic anemia, anemia in myelodysplastic diseases, chronic inflammatory diseases, AIDS, cancer).
Prevention of anemia in premature newborns born with a body weight of 750-1500 g until the 34th week of pregnancy.
To increase the volume of donor blood, intended for subsequent autotransfusion in order to avoid blood transfusions.
Contraindications Uncontrolled hypertension, suffered myocardial infarction or stroke of the brain during the previous month, unstable angina, history of thromboembolism, hypersensitivity to epoetin beta.
Dosage Doses, the scheme and duration of treatment are set individually, depend on the severity of anemia, the severity of the patient's condition, the nature of the disease. Introduce sc and iv. Initial doses - 50-150 IU / kg, the frequency of administration - an average of 3 times a week. Side effects From the cardiovascular system: possible arterial hypertension, hypertensive crisis.
From the side of the central nervous system: encephalopathy is possible (more often with hypertensive crises), headache, confusion.
From the coagulation system: rarely - thrombocytosis, thrombotic complications.
From the side of metabolism: rarely - hyperkalemia.
Drug Interactions With the simultaneous use of drugs that affect hematopoiesis (such as iron preparations), the stimulating effect of epoetin beta can be enhanced. special instructions Use with caution in epilepsy, thrombocytosis, liver failure, vascular insufficiency, with malignant neoplasms; in patients with nephrosclerosis who are not receiving hemodialysis, since a more rapid deterioration in kidney function is possible.
The effectiveness of treatment decreases with iron deficiency in the body, with infectious and inflammatory diseases, hemolysis.
Impact on the ability to drive vehicles and manage mechanisms
During the treatment period, one should refrain from occupations requiring increased attention and speed of psychomotor reactions.
Pregnancy and lactemia In pregnancy and during lactation epoetin beta is used only if the intended benefit of treatment for the mother exceeds the potential risk of side effects in the mother, fetus or child.
In experimental studies, teratogenic effects have not been identified.
In case of violations of kidney function Use with caution in liver failure. With violations of liver function They are used with caution in patients with nephrosclerosis who are not receiving hemodialysis, since a more rapid deterioration in kidney function is possible. Description of the drug ERITROPOETIN is based on an approved instruction for use and approved by the manufacturer.
Erythropoietin [Epoetin Beta] is used as a stimulant (dope) in some sports (jumps, boxing, running, walking, cross-country skiing, biathlon, triathlon, etc.). The ability of the muscles to withstand endurance exercises depends on the supply of oxygen. Therefore, the main reason why athletes use this stimulator is to improve the delivery of oxygen to the muscles.